St. Jude Medical Launches Visualization Tool to Improve EP Lab Workflow

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the launch of the VantageView™ System in the United States and Europe. The VantageView System is a state-of-the-art, high-definition (HD) monitor that eliminates the need for multiple monitors and enhances workflow by improving the visualization of critical case information in the electrophysiology (EP) lab.

VantageView(TM) System includes a 56 inch high-definition monitor that can display up to eight video images simultaneously (Photo: Business Wire)

Rapid technology advances have resulted in more equipment requiring visual displays in the EP lab, which can potentially hinder the flow of the procedure and make it challenging for clinicians to view the right screen at the right time during a case. The VantageView System was designed to consolidate the display of information from multiple technologies into one centralized location, displaying images from mapping systems, recording systems, fluoroscopy and ultrasound, among others.

The system includes a 56 inch HD monitor that can display up to eight video images simultaneously with four times the resolution seen in standard 1080p consumer monitors. The VantageView System offers exceptional image quality with greater detail than the monitors typically used in EP labs today. In addition to enhanced image quality, the VantageView System can be seamlessly integrated with the EP lab’s multiple diagnostic and treatment systems, allowing clinicians to customize screen displays and more easily view and control patient and procedure information.

“For the treatment of cardiac arrhythmias, improving procedural workflow is an important way to create efficiencies and manage the cost of delivering care,” said Jane J. Song, president of the St. Jude Medical Atrial Fibrillation Division. “By adding a large screen to replace several smaller screens, the VantageView System can better integrate labs and create those efficiencies.”

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended April 2, 2011. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6760554&lang=en

SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024